FDA approval for Vercise Primary Cell (PC) and Vercise Gevia deep brain stimulation (DBS) systems, developed by Boston Scientific has been earned in the U.S. Apart from the FDA approval, European regulatory clearance for Parkinson’s, dystonia, and essential tumor was also received. The systems have been designed to manage symptoms of the disease of Parkinson’s.
Aspects such as précised control of the location, direction, shape and range of the electrical stimulation are well taken care of with the company’s innovative Vercise Cartesia directional lead that is featured in the devices.
Along with as many as eight independent electrodes in the lead; the system in response to the changing impedance measured in the brain, can effortlessly adjust the activities of the electrodes.
MD, Director of the Barrow Center of Neuromodulation in Phoenix, Arizona and the first center to implant the new system; Dr. Francisco Ponce explained that the progression of Parkinson’s disease requires a therapy that can evolve with the patient as time passes.
He further added that when compared to the pre existing similar systems in the market, the latest approved Vercise Directional DBS Systems offer devices that are smaller and have been engineered in a manner that gives them longer rechargeable battery life. They also offer stimulation that can be customized, unlike the current systems available in market today. Thus, it is only natural to expect that given such factors, patient comfort will automatically be taken care of as their needs will be catered to, by the physicians much more efficiently.
Vercise Gevia and Vercise Primary Cell offer similar capabilities However, Gevia is rechargeable and a span of 15 years is qupted for the battery to last before replacement, while Primary Cell can last up to 3 years and is non- rechargeable.